Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04055649 is registered in ClinicalTrials.gov with Ira Winer as lead sponsor.

NCT NCT04055649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04055649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lead sponsor
Ira Winer
Phase
Phase 2
Overall status
Recruiting
Start date
January 21, 2020
Completion date
May 28, 2027
Enrollment
62 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant ovarian epithelial tumor, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, refractory fallopian tube carcinoma, refractory ovarian carcinoma, refractory primary peritoneal carcinoma